A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.

NCT ID: NCT02878330

Last Updated: 2019-10-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

1453 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-03

Study Completion Date

2018-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy preterm infants who are between 29 and 35 weeks gestational age (GA) and entering their first Respiratory Syncytial Virus (RSV) season.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This pivotal Phase 2b study will determine if MEDI8897 will be efficacious in reducing medically attended RSV-confirmed lower respiratory tract infections (LRTI) in healthy preterm infants entering their first RSV season. The population to be enrolled is healthy preterm infants born between 29 weeks 0 days and 34 weeks 6 days GA who would not receive RSV prophylaxis. A total of 1500 infants will be randomized 2:1 to receive either MEDI8897 or placebo. Participants will be followed for 360 days after dosing. Enrollment is planned at approximately 197 sites across the USA, Canada, Europe, and the Southern Hemisphere.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Syncytial Virus Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.

MEDI8897 50 mg

Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.

Group Type EXPERIMENTAL

MEDI8897

Intervention Type DRUG

A single IM dose of 50 mg on Day 1 of the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MEDI8897

A single IM dose of 50 mg on Day 1 of the study.

Intervention Type DRUG

Placebo

A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA.
2. Infants who are entering their first full RSV season at the time of screening.

Exclusion Criteria

1. Meets American Academy of Pediatrics (AAP) or other local criteria to receive commercial palivizumab.
2. Any fever (\>= 100.4°F \[\>= 38.0°C\], regardless of route) or lower respiratory illness within 7 days prior to randomization.
3. Acute illness (defined as the presence of moderate or severe signs and symptoms) at the time of randomization.
4. Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection.
5. Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including maternal RSV vaccination.
Maximum Eligible Age

365 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MedImmune LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Birmingham, Alabama, United States

Site Status

Research Site

Anaheim, California, United States

Site Status

Research Site

Anaheim, California, United States

Site Status

Research Site

Downey, California, United States

Site Status

Research Site

Long Beach, California, United States

Site Status

Research Site

Los Angeles, California, United States

Site Status

Research Site

Paramount, California, United States

Site Status

Research Site

San Diego, California, United States

Site Status

Research Site

West Covina, California, United States

Site Status

Research Site

Aurora, Colorado, United States

Site Status

Research Site

Colorado Springs, Colorado, United States

Site Status

Research Site

Hartford, Connecticut, United States

Site Status

Research Site

Gainesville, Florida, United States

Site Status

Research Site

Orlando, Florida, United States

Site Status

Research Site

South Miami, Florida, United States

Site Status

Research Site

Atlanta, Georgia, United States

Site Status

Research Site

Augusta, Georgia, United States

Site Status

Research Site

Chicago, Illinois, United States

Site Status

Research Site

Oak Lawn, Illinois, United States

Site Status

Research Site

Park Ridge, Illinois, United States

Site Status

Research Site

South Bend, Indiana, United States

Site Status

Research Site

Woburn, Massachusetts, United States

Site Status

Research Site

Detroit, Michigan, United States

Site Status

Research Site

Jackson, Mississippi, United States

Site Status

Research Site

Columbia, Missouri, United States

Site Status

Research Site

Lincoln, Nebraska, United States

Site Status

Research Site

Omaha, Nebraska, United States

Site Status

Research Site

Omaha, Nebraska, United States

Site Status

Research Site

Omaha, Nebraska, United States

Site Status

Research Site

Mineola, New York, United States

Site Status

Research Site

New Hyde Park, New York, United States

Site Status

Research Site

Stony Brook, New York, United States

Site Status

Research Site

Syracuse, New York, United States

Site Status

Research Site

Boone, North Carolina, United States

Site Status

Research Site

Raleigh, North Carolina, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Cleveland, Ohio, United States

Site Status

Research Site

Columbus, Ohio, United States

Site Status

Research Site

Columbus, Ohio, United States

Site Status

Research Site

Dayton, Ohio, United States

Site Status

Research Site

Oklahoma City, Oklahoma, United States

Site Status

Research Site

Gresham, Oregon, United States

Site Status

Research Site

Erie, Pennsylvania, United States

Site Status

Research Site

Pittsburgh, Pennsylvania, United States

Site Status

Research Site

Charleston, South Carolina, United States

Site Status

Research Site

North Charleston, South Carolina, United States

Site Status

Research Site

Sioux Falls, South Dakota, United States

Site Status

Research Site

Memphis, Tennessee, United States

Site Status

Research Site

Edinburg, Texas, United States

Site Status

Research Site

Fort Worth, Texas, United States

Site Status

Research Site

Galveston, Texas, United States

Site Status

Research Site

Longview, Texas, United States

Site Status

Research Site

San Antonio, Texas, United States

Site Status

Research Site

Layton, Utah, United States

Site Status

Research Site

Orem, Utah, United States

Site Status

Research Site

Syracuse, Utah, United States

Site Status

Research Site

Seattle, Washington, United States

Site Status

Research Site

Huntington, West Virginia, United States

Site Status

Research Site

Morgantown, West Virginia, United States

Site Status

Research Site

Madison, Wisconsin, United States

Site Status

Research Site

Bahía Blanca, , Argentina

Site Status

Research Site

Guaymallen Mendoza, , Argentina

Site Status

Research Site

Parkville, , Australia

Site Status

Research Site

Subiaco, , Australia

Site Status

Research Site

Ghent, , Belgium

Site Status

Research Site

Mons, , Belgium

Site Status

Research Site

Botucatu, , Brazil

Site Status

Research Site

Campinas, , Brazil

Site Status

Research Site

Canoas, , Brazil

Site Status

Research Site

Curitiba, , Brazil

Site Status

Research Site

Juiz de Fora, , Brazil

Site Status

Research Site

Passo Fundo, , Brazil

Site Status

Research Site

Pleven, , Bulgaria

Site Status

Research Site

Plovdiv, , Bulgaria

Site Status

Research Site

Rousse, , Bulgaria

Site Status

Research Site

Sofia, , Bulgaria

Site Status

Research Site

Sofia, , Bulgaria

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Maipú, , Chile

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Santiago, , Chile

Site Status

Research Site

Valdivia, , Chile

Site Status

Research Site

Viña del Mar, , Chile

Site Status

Research Site

Havlíčkův Brod, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Prague, , Czechia

Site Status

Research Site

Tallinn, , Estonia

Site Status

Research Site

Tartu, , Estonia

Site Status

Research Site

Tampere, , Finland

Site Status

Research Site

Turku, , Finland

Site Status

Research Site

Bordeaux, , France

Site Status

Research Site

Brest, , France

Site Status

Research Site

Bron, , France

Site Status

Research Site

Caen, , France

Site Status

Research Site

Dijon, , France

Site Status

Research Site

Tours, , France

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Gyula, , Hungary

Site Status

Research Site

Kecskemét, , Hungary

Site Status

Research Site

Miskolc, , Hungary

Site Status

Research Site

Nagykanizsa, , Hungary

Site Status

Research Site

Nyireyghaza, , Hungary

Site Status

Research Site

Sopron, , Hungary

Site Status

Research Site

Szeged, , Hungary

Site Status

Research Site

Szekszárd, , Hungary

Site Status

Research Site

Veszprém, , Hungary

Site Status

Research Site

Genova, , Italy

Site Status

Research Site

Padua, , Italy

Site Status

Research Site

Torino, , Italy

Site Status

Research Site

Verona, , Italy

Site Status

Research Site

Jēkabpils, , Latvia

Site Status

Research Site

Riga, , Latvia

Site Status

Research Site

Valmiera, , Latvia

Site Status

Research Site

Kaunas, , Lithuania

Site Status

Research Site

Kaunas, , Lithuania

Site Status

Research Site

Christchurch, , New Zealand

Site Status

Research Site

Otahuhu, , New Zealand

Site Status

Research Site

Wellington, , New Zealand

Site Status

Research Site

Bydgoszcz, , Poland

Site Status

Research Site

Gdansk, , Poland

Site Status

Research Site

Krakow, , Poland

Site Status

Research Site

Krakow, , Poland

Site Status

Research Site

Łęczna, , Poland

Site Status

Research Site

Cape Town, , South Africa

Site Status

Research Site

Cape Town, , South Africa

Site Status

Research Site

Claremont, , South Africa

Site Status

Research Site

Durban, , South Africa

Site Status

Research Site

Johannesburg, , South Africa

Site Status

Research Site

Johannesburg, , South Africa

Site Status

Research Site

Pietermaritzburg, , South Africa

Site Status

Research Site

Pretoria, , South Africa

Site Status

Research Site

Alicante, , Spain

Site Status

Research Site

Boadilla del Monte, , Spain

Site Status

Research Site

Córdoba, , Spain

Site Status

Research Site

Granada, , Spain

Site Status

Research Site

Lleida, , Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Madrid, , Spain

Site Status

Research Site

Málaga, , Spain

Site Status

Research Site

Sant Cugat del Vallès, , Spain

Site Status

Research Site

Sant Joan d'Alacant, , Spain

Site Status

Research Site

Santiago de Compostela, , Spain

Site Status

Research Site

Valencia, , Spain

Site Status

Research Site

Stockholm, , Sweden

Site Status

Research Site

Stockholm, , Sweden

Site Status

Research Site

Adana, , Turkey (Türkiye)

Site Status

Research Site

Ankara, , Turkey (Türkiye)

Site Status

Research Site

Antalya, , Turkey (Türkiye)

Site Status

Research Site

Izmir, , Turkey (Türkiye)

Site Status

Research Site

Izmir, , Turkey (Türkiye)

Site Status

Research Site

Kocaeli, , Turkey (Türkiye)

Site Status

Research Site

Brighton, , United Kingdom

Site Status

Research Site

Bristol, , United Kingdom

Site Status

Research Site

London, , United Kingdom

Site Status

Research Site

Oxford, , United Kingdom

Site Status

Research Site

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Brazil Bulgaria Canada Chile Czechia Estonia Finland France Hungary Italy Latvia Lithuania New Zealand Poland South Africa Spain Sweden Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Langer S, Holzapfel S, August L, Badura A, Wellmann S, Mack I. Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence? Vaccine. 2024 Oct 3;42(23):126050. doi: 10.1016/j.vaccine.2024.06.018. Epub 2024 Jun 19.

Reference Type DERIVED
PMID: 38902186 (View on PubMed)

Ahani B, Tuffy KM, Aksyuk AA, Wilkins D, Abram ME, Dagan R, Domachowske JB, Guest JD, Ji H, Kushnir A, Leach A, Madhi SA, Mankad VS, Simoes EAF, Sparklin B, Speer SD, Stanley AM, Tabor DE, Hamren UW, Kelly EJ, Villafana T. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun. 2023 Jul 19;14(1):4347. doi: 10.1038/s41467-023-40057-8.

Reference Type DERIVED
PMID: 37468530 (View on PubMed)

Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simoes EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556.

Reference Type DERIVED
PMID: 32726528 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D5290C00003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

MEDI-557 Adult Dosing
NCT01562938 COMPLETED PHASE1